Insider Selling: iRadimed (NASDAQ:IRMD) CEO Sells $501,900.00 in Stock

iRadimed Corporation (NASDAQ:IRMD) CEO Roger Susi sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, March 23rd. The shares were sold at an average price of $100.38, for a total transaction of $501,900.00. Following the transaction, the chief executive officer directly owned 2,235,000 shares of the company’s stock, valued at approximately $224,349,300. This represents a 0.22% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

iRadimed Trading Down 1.4%

iRadimed stock opened at $97.36 on Friday. iRadimed Corporation has a 1-year low of $47.48 and a 1-year high of $107.90. The firm has a market capitalization of $1.24 billion, a PE ratio of 55.63 and a beta of 1.12. The firm’s 50 day simple moving average is $100.37 and its 200 day simple moving average is $90.46.

iRadimed (NASDAQ:IRMD) last announced its quarterly earnings results on Tuesday, February 10th. The medical equipment provider reported $0.54 EPS for the quarter, beating the consensus estimate of $0.49 by $0.05. The firm had revenue of $22.69 million during the quarter, compared to the consensus estimate of $21.60 million. iRadimed had a net margin of 26.82% and a return on equity of 23.83%. iRadimed has set its Q1 2026 guidance at 0.440-0.480 EPS and its FY 2026 guidance at 2.060-2.210 EPS. Research analysts forecast that iRadimed Corporation will post 1.66 earnings per share for the current year.

iRadimed Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, March 6th. Investors of record on Monday, February 23rd were paid a dividend of $0.20 per share. This is a positive change from iRadimed’s previous quarterly dividend of $0.17. This represents a $0.80 annualized dividend and a yield of 0.8%. The ex-dividend date of this dividend was Monday, February 23rd. iRadimed’s dividend payout ratio is 45.71%.

Analyst Ratings Changes

Several research firms have weighed in on IRMD. Lake Street Capital reaffirmed a “buy” rating and issued a $120.00 price target on shares of iRadimed in a report on Wednesday, February 11th. Weiss Ratings reissued a “buy (b-)” rating on shares of iRadimed in a report on Monday, December 29th. Finally, Roth Mkm restated a “buy” rating and issued a $120.00 price objective on shares of iRadimed in a research report on Tuesday, February 10th. Three equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $120.00.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. CWM LLC raised its position in iRadimed by 62.2% during the third quarter. CWM LLC now owns 550 shares of the medical equipment provider’s stock valued at $39,000 after purchasing an additional 211 shares in the last quarter. Quarry LP purchased a new position in shares of iRadimed in the 3rd quarter worth about $40,000. Farther Finance Advisors LLC boosted its holdings in shares of iRadimed by 827.1% in the 4th quarter. Farther Finance Advisors LLC now owns 445 shares of the medical equipment provider’s stock worth $43,000 after purchasing an additional 397 shares in the last quarter. Tower Research Capital LLC TRC increased its position in shares of iRadimed by 191.1% during the 2nd quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock valued at $45,000 after purchasing an additional 495 shares during the last quarter. Finally, State of Alaska Department of Revenue bought a new position in shares of iRadimed during the 3rd quarter valued at about $47,000. 92.34% of the stock is currently owned by hedge funds and other institutional investors.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.